This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, J. H. Articles by Bloch, D. B. Search for Related Content PubMed PubMed Citation Articles by Yu, J. H. Articles by Bloch, D. B.

Restoration of Promyelocytic Leukemia Protein-Nuclear Bodies in Neuroblastoma Cells Enhances Retinoic Acid Responsiveness

Departments of Medicine and Pediatrics, Harvard Medical School; ¹ Center for Immunology and Inflammatory Diseases and the ² Cardiovascular Research Center of the General Medical Services, Massachusetts General Hospital; and ³ Department of Pediatric Oncology, Dana-Farber Cancer Institute and the Department of Medicine, Children’s Hospital, Boston, Massachusetts

Neuroblastoma is the most common solid tumor of infancy and is believed to result from impaired differentiation of neuronal crest embryonal cells. The promyelocytic leukemia protein (PML)-nuclear body is a cellular structure that is disrupted during the pathogenesis of acute promyelocytic leukemia, a disease characterized by impaired myeloid cell differentiation. During the course of studies to examine the composition and function of PML-nuclear bodies, we observed that the human neuroblastoma cell line SH-SY5Y lacked these structures and that the absence of PML-nuclear bodies was a feature of N- and I-type, but not S-type, neuroblastoma cell lines. Induction of neuroblastoma cell differentiation with 5-bromo-2'deoxyuridine, all-trans-retinoic acid, or IFN- induced PML-nuclear body formation. PML-nuclear bodies were not detected in tissue sections prepared from undifferentiated neuroblastomas but were present in neuroblasts in differentiating tumors. Expression of PML in neuroblastoma cells restored PML-nuclear bodies, enhanced responsiveness to all-trans-retinoic acid, and induced cellular differentiation. Pharmacological therapies that increase PML expression may prove to be important components of combined modalities for the treatment of neuroblastoma.

This article has been cited by other articles:

				C. Cetinkaya, A. Hultquist, Y. Su, S. Wu, F. Bahram, S. Pahlman, I. Guzhova, and L.-G. Larsson Combined IFN-{gamma} and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells Mol. Cancer Ther., October 1, 2007; 6(10): 2634 - 2641. [Abstract] [Full Text] [PDF]